Navigation Links
Monoclonal Antibody Induces Death in Liver Cancer Cells

Researchers at the University of Pittsburgh School of Medicine have found that a newly available monoclonal antibody has the potential to induce death in liver cancer cells.

In a study, the monoclonal antibodies' use demonstrated significantly reduces tumour cell proliferation and survival in human and mouse hepotocellular cancer (HCC) cell lines.

The researchers say that the new findings have significant implications not only for the treatment of live cancer, but also for various other types of cancer-skin cancer, brain tumours, gastrointestinal tumours, prostate tumours, ovarian cancer and leukaemia.

According to the background information in an article published in the journal published in Molecular Cancer Therapeutics, most cases of HCC are secondary to either a viral hepatitis infection or cirrhosis of the liver.

Despite recent advances, it remains a disease of grim prognosis due to the poorly understood mechanism of how the disease originates and spreads. Most patients live only a short time after diagnosis.

Dr. Satdarshan P. Singh Monga, Associate Professor in the division of cellular and molecular pathology at the university, directed his colleagues to obtain rat and human liver cancer cell lines so as to analysed the cell lines for the levels of expression of an receptor tyrosine kinase (RTK) protein, shown to be highly active in the liver of HCC patients in some previous studies, known as platelet-derived growth factor receptor-alpha (PDGFRa).

The researchers also analysed the cells for their level of activation of the PDGFRa gene.

It was found that at an early foetal stage of liver development in the mouse, the level of expression of PDGFRa was 37 times higher compared to later stages of development in the adult mouse liver. The researchers also found significantly higher levels of PDGFRa in rat and human liver cancer cell lines as compared to normal ce lls in culture.

When both human and mouse live cancer cell lines were treated with a monoclonal antibody, tumour cell proliferation significantly decreased and programmed cell death (apoptosis) increased four to 18 fold, as compared to normal control cells.

The researchers say that the results depict PDGFRa as a possible new therapeutic target for the treatment of HCC.

"We are very excited because this is the first targeted therapy for liver cancer. Other therapies have some modest benefits, but no one knows exactly how they work. We now have identified a pathway that appears to be overly active in more than 70 per cent of the cancers we examined and, when targeted, leads to significant reduction in tumour cell proliferation and survival," said Dr. Monga.

He also says that targeting the PDGFRa pathway in liver cancer cells does not affect normal liver cells, making the treatment relatively non-toxic.

"Normally, regenerating liver cells are not exclusively dependent on this pathway, and it is not overly active in other types of cells. So this monoclonal antibody is a highly targeted treatment for this disease," he added.


'"/>




Related medicine news :

1. Therapeutic Monoclonal Antibody Production Is More Profitable Than Small Molecule Drugs
2. Monoclonal antibodies show promise in treatment of blood cancer
3. Monoclonal Anti-Body To Revolutionize Brain Cancer Treatment
4. Monoclonal Antibody based system for Anthrax detection
5. Monoclonal Antibody Reduces Exacerbations in Asthmatics
6. Survival of Mice With Human Breast Cancer Extended by Monoclonal Antibodies
7. A New Monoclonal Antibody Kills Cancer Cells
8. Human Antibody That Can Block SARS
9. Cuba Registers New Antibody
10. Single Sugar Enables Antibody to Treat Inflammation
11. Anti-rejection Therapy a Boon for Patients With "anti-donor" Antibody Levels
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/17/2017)... ... January 17, 2017 , ... ... assistance to families and business professionals throughout central Colorado, is joining local nonprofit ... , The Aurora Warms The Night organization is committed to breaking the cycle ...
(Date:1/17/2017)... ... January 17, 2017 , ... Physicians Education ... Lee as keynote speaker for the 34th Annual Miami Breast Cancer Conference®, on ... announcement, PER® president, Phil Talamo, said, “We are delighted to have Sandra Lee ...
(Date:1/17/2017)... ... , ... Today, FloSports , a global leader in live digital sports ... of a long-term extension of their media partnership. The partnership, which began in 2013, ... sport’s premier events exclusively on FloWrestling.com as well as usage of the FloArena meet ...
(Date:1/16/2017)... ... January 16, 2017 , ... California Southern University has named Dr. Steven ... Board of Trustees and as a core faculty member, teaching master’s and doctoral courses ... of psychology at Pepperdine University, where he earned his Doctor of Psychology degree in ...
(Date:1/16/2017)... ... ... Anybody who may be looking for a substance abuse rehabilitation program with ... a holistic treatment center for addiction located in Marne, MI. This video, which can ... and staff that visited the 2016 Recovery Palooza support event in nearby Grand Rapids. ...
Breaking Medicine News(10 mins):
(Date:1/17/2017)... -- Interpace Diagnostics Group, Inc., (NASDAQ: IDXG ), ... and pathology services for evaluating risks of cancer, announced ... 13, 2017 from the NASDAQ Listing Qualifications notifying the ... of the NASDAQ Stock Market to maintain a minimum ... The letter noted that for the last 10 days ...
(Date:1/17/2017)... Research and Markets has announced the addition ... their offering. ... The global laparotomy sponges market to grow at a CAGR of ... Sponges Market 2016-2020, has been prepared based on an in-depth market ... landscape and its growth prospects over the coming years. The report ...
(Date:1/17/2017)... , Jan. 17, 2017 Tempus, ... cancer care, and University Hospitals Seidman Cancer Center ... by making genomic data, advanced molecular analysis and ... researchers, physicians and healthcare providers. ... provide genomic and transcriptomic sequencing and analysis for ...
Breaking Medicine Technology: